MAGE cancer-associated proteins are commonly expressed in multiple myeloma cells. The purpose of this study is to evaluate a vaccine that targets the MAGE-A3 protein. The vaccine is designed to train a patient’s own immune system to identify and fight myeloma cells that produce MAGE-A3. It will be used in combination with autologous stem cell transplantation as “consolidation” therapy (which is given after initial “induction” chemotherapy).
Researchers will determine the safety and side effects of MAGE-A3 vaccination, study how patients’ immune systems respond to the vaccine, and see how the vaccine affects multiple myeloma.